Traditionally, scientists have used 2D cell cultures as in vitro models in drug screening studies due to their simplicity and scalability. However, 2D cell models do not recapitulate the complexity of ...

iXCells’ mission is to empower life science researchers and patient foundations to advance personalized therapies and accelerate discovery of better medicines for a healthier future. iXCells’ cell ...

ALS is a heterogeneous disease. While 10-15% of cases are linked to inherited mutations, nearly 85% are sporadic.

Yusuf Roohani, PhD, machine learning group lead at the Arc Institute, is among a team of researchers training artificial intelligence (AI) models with transcriptome data to predict how cell gene ...

Researchers have developed a vascularized organoid model of hormone secreting cells in the pancreas. The advance promises to improve diabetes research and cell-based therapies. Researchers led by ...

Early detection of safety liabilities of new therapies is a critical biopharmaceutical challenge. Addressing this challenge could significantly advance drug discovery. Advanced human cell models, ...

A new global initiative launched today aims to close a critical gap in ALS/MND drug discovery - current cell models used for ...

State-of-the-art AI model accurately predicting unseen biological experiments X-Cell is trained on X-Atlas/Pisces, the largest and most context-diverse genome-wide perturbation dataset ever reported ...

Single-cell sequencing reveals cellular heterogeneity within models, while advanced imaging captures dynamic processes in living organoids. These tools, combined with rigorous validity assessment, ...